Imaging Evaluation of Prostate Cancer with 18F-fluorodeoxyglucose PET/CT: Utility and Limitations

摘要

Prostate cancer poses a major public health problem in the developed countries. The remarkable biological and clinical heterogeneity of prostate cancer provides unique opportunities as well as challenges for the diagnostic imaging evaluation of this prevalent disease. The disease is characterized by a natural history that ranges from localized slowly-growing hormone-dependent tumor progressing to metastatic hormone-refractory disease. Positron emission tomography (PET) is an ideal imaging tool for noninvasive interrogation of the underlying tumor biology. Fluorine-18 fluorodeoxyglucose (FDG) is the most common PET radiotracer used for oncologic applications which is based upon elevated glucose metabolism in malignant tissue in comparison to normal tissue. FDG uptake in the prostate cancer depends on tumor differentiation with low accumulation in well-differentiated tumors and high uptake in aggressive poorly-differentiated tumors. Cumulative current evidence suggests that FDG PET may be useful in detection of disease in a small fraction of patients with biochemical recurrence, in the imaging evaluation of extent and treatment response in metastatic disease and in prediction of patient outcome.